KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Common Equity (2023 - 2025)

Biocryst Pharmaceuticals' Common Equity history spans 9 years, with the latest figure at -$119.2 million for Q4 2025.

  • For Q4 2025, Common Equity rose 74.96% year-over-year to -$119.2 million; the TTM value through Dec 2025 reached -$119.2 million, up 74.96%, while the annual FY2025 figure was -$119.2 million, 74.96% up from the prior year.
  • Common Equity reached -$119.2 million in Q4 2025 per BCRX's latest filing, up from -$387.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$119.2 million in Q4 2025 to a low of -$476.2 million in Q1 2024.
  • Average Common Equity over 3 years is -$405.0 million, with a median of -$436.8 million recorded in 2025.
  • Peak YoY movement for Common Equity: tumbled 45.05% in 2024, then soared 74.96% in 2025.
  • A 3-year view of Common Equity shows it stood at -$455.5 million in 2023, then fell by 4.48% to -$475.9 million in 2024, then skyrocketed by 74.96% to -$119.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Common Equity are -$119.2 million (Q4 2025), -$387.9 million (Q3 2025), and -$421.6 million (Q2 2025).